Phase 1 NK-102: Umbilical Cord Blood NK Cells with Soluble IL-15 & PD-L1 Expression

This Phase 1 dose escalation trial by University of California, Irvine examines the safety and maximum tolerated dose of NK-102, an engineered natural killer cell therapy expressing soluble IL-15 and PD-L1, administered alone or with atezolizumab—a PD-L1 targeting monoclonal antibody. The study enrolls patients with advanced, metastatic, or recurrent non-small cell lung cancer who have progressed after prior PD-1/PD-L1 inhibitor therapy, aiming to define dosing parameters for this novel immunotherapy approach.